Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Year 1 POM > Emerging treatments > Flashcards

Emerging treatments Flashcards

1
Q

What pathways with metabolism are usually affected with genetic disease?

A
  • Usually alternate product
  • Carbohydrate
  • Fatty acid
  • Proteins
  • lack enzyme
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are some examples of inborn errors of metabolism disease?

A

PKU
MCAD Deficiency
Maple Syrup Urine Disease
Homocystinuria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is PKU caused by? What does this cause?

A

1 Caused by lack of phhenylanine hydroxylase (so not transformed into tyrosine)

  1. So increased levels of phenylanine which turns into phenylketones
  2. Both of these are neurotoxins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What does untreated PKU lead to?

A 
-Major cognitive impairment 
behavioural difficulties
fairer skin, hair and eyes than siblings
-lack of melanin
-recurrent vomiting
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How is PKU treated?

A

Treated with low protein diet – Tyrosine supp
Before treatment need to identify cause
Possible before gene identified - biochemistry
-Lack of PAH 1960’s PKU screening introduced (just measuring levels can’t see gene as not known)
-1984 PAH mutation identified

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is Haemophilia?

A
  • Blood clotting disorder
  • Known since ancient times
  • Uncontrolled bleeding
  • Bleeding into joints
  • excruciating pain
  • Bleeding into brain
  • Internal bleeding
  • Untreated fatal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How do you treat haemophilia?

A 
1968 - First FVIII concentrate available
1970s - Freeze-dried plasma-derived factor concentrates available
However Not all good news
1970-1980s
5000-30000 given clotting factors contaminated with HIV and hepatitis
2500 so far died
1980s - heat treat products kill virus
1980s - Factor VIII gene cloned 
1990s – Recombinant Factor VII treatment
So now pure and disease free
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How is Growth hormone deficiency treated?

A

Injection growth hormone now recombinant (cadaver derived cjd)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How is lysosomal storage diseases treated?

A

-This affects lysosomal breakdown

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How is Fabry disease treated?

A

•Injection recombinant alpha galactosidase A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How is Pompe disease treated?

A

•Injection of alpha glucosidase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How are drugs approved?

A
  • Discovery
  • Animals
  • 3 clinical phase
  • Approval EMA FDA
  • For NHS, NICE and look at evidence, cost and value for money
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are some therapies targeting proteins?

A
  • These are treatments not cures

- Try to normalise function of mutant protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Why are pharmalogical chaperons used?

A
  1. Protein folding is complex sometime fails
  2. System in ER degrades misfolded proteins
  3. Some mutations prevent proteins folding properly
  4. Subject degradation pathway
    If folded correctly would be active
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is Fabry disease?

A

deficiency α-galactosidase A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is a result of Fabry disease?

A

Build up of globotriaosylceramide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is a pharmacological chaperon for Fabry disease?

A

-Some mutations cause misfolding
-Migalastat small molecule chaperone
Stabilises enzyme in correct shape
NICE approved Feb 2017
-Mutation specific (have to same mutation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are pharmacological modulators?

A

Commonly used drugs:
1. Receptor agonists/antagonist
2. Ion channel activators/blockers
-Can design one that has these effects on mutant receptor or channel
- e.g. Bcl-abl Kinase inhibitors (Philadelphia chromosome)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is cystic fibrosis?

A
  • Defective chloride channel

- Mutations (33) cause channel not to open

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is a treatment for cystic fibrosis?

A
  • Design a drug which causes activation - Ivacaftor binds tochannel and make it more open
  • Is mutation specific (treatment won’t work without this mutation)
21
Q

How is cystic fibrosis caused treated with combination therapy?

A
  • Defective chloride channel
  • One mutation (f508del) misfolded, inactive channel
  • Treat with combination chaperone and activator
  • Orkambi (Ivacaftor/lumacaftor) – -NICE approved Oct ’19
  • Not cure does improve lung function
22
Q

What is a stop Condon read through?

A

Some diseases caused by non-sense mutation
-premature stop codon
-This prevents protein production
Can drugs be used to prevent this

23
Q

What is amino glycoside antibiotic?

A

-Aminoglycoside antibiotics bind to ribosome
-Causemistranslation
Drugs based on these → read through non-sense mutations

24
Q

How is stop codon read through used in DMD and BMD?

A

Duchenne muscular dystrophy – premature stop
-Becker muscular dystrophy – missing section
-If read through premature stop DMD → BMD
-Ataluren – approved in EU not in US
NICE approved – June 2016
-Non-sense mutation specific

25
Q

Why is gene therapy hard?

A

-Achieving specificity
-Getting therapy to right place
-maintain expression

26
Q

Why is gene therapy easy in theory?

A
  1. Recessive disease - replace defective gene

2, Dominant disease – delete defective gene

27
Q

When is it easier to do gene therapy?

A

Much easier to achieve in vitro than in vivo

28
Q

What does in vivo mean?

A

In the living

29
Q

What doe ex vivo mean?

A

out of the living

30
Q

What does in Vitro mean?

A

In glass

31
Q

How do you undertake mitochondrially inherited disease therapy?

A
  • Only effective therapy
  • Requires IVF
  • Take DNA from fertilised patient egg
  • Transfer to donor egg normal mitochondria
32
Q

What are the two ways to do mitochondrial inherited disease therapy?

A
  1. Maternal spindle transfer

2. Pro-nuclear transfer

33
Q

What is maternal spindle transfer?

A
  1. Chromosomes are removed from an unfertilised egg that has mutated mitochondrial DNA
  2. These are added to an unfertilised donor egg that has had its nucleus removed
  3. This fused egg is fertilised in vitro
  4. The egg develops normally to from an embryo
34
Q

What is pronuclear transfer?

A
  1. An egg with mutated mitochondria DNA is fertilised in vitro
  2. The resulting pro-nucleus is removed
  3. This is transferred to a fertilised donor egg that has had its pronucleus removed
  4. The fused egg develops normally
35
Q

What are the views in mitochondrial inherited disease therapy?

A 
Approved for use in UK
Not without controversy 
Popularly know as three-parent babies
Mitochondrial DNA 16 569bp
Genome 3 088 269 832bp
36
Q

What is virus gene therapy?

A

Can engineer virus to carry therapeutic gene

37
Q

What are examples of viruses used?

A

AAV
Adenovirus
Lentivirus – HIV
Vaccinia

38
Q

What does the virus choice depends on?

A
  • Virus choice depends on target tissue

- Amount of DNA limited depends on virus

39
Q

What is the Chimeric Antigen Receptor T cell used? (CAR-T)

A

-To treat cancer
-T-cell receptorantigen bound to MHC
-Low affinity
-CAR – recognise antigen directly + higher affinity
-Variable region monoclonal antibody scFv
-recognise cancer cell
-T cell receptor and co-receptor signalling domain

40
Q

What is the process of CAR T cell therapy?

A

1, Isolate patients T-cells

  1. T-Cells expanded
  2. Transfected with CAR – lentivirus
  3. CAR-T cells expanded
  4. Reinfused into patient (suppress patients T cells)
  5. Currently approved for some B-cell lymphomas
41
Q

When do you use CAR T cell therapy?

A
  • If other therapies haven’t worked
  • Can cause cytokine release syndrome, neurological damage.
  • Being investigated for solid tumours
42
Q

How is in vivo gene therapy supplement used?

A

Useful lack of a functional gene

43
Q

How do you carry out in vivo gene therapy?

A

-Use a virus to carry in working copy
1. Can inject systemically
2. Can inject locally
-Eye
-Spine
-Brain
Many treatments in development

44
Q

What is Leber congenital amaurosis type 2?

A
  1. Recessive disease caused by mutation RPE65

2. Progressive blindness – loss of retinal cells

45
Q

How is Leber congenital amaurosis type 2 treated?

A
  • Luxturna rAAV2 expressing RPE65
  • Not cure – greatly improves vision
  • Patients need sufficient remaining cells
  • EMA approved Nov 2018
  • NICE approved Sept 2019
46
Q

What are Anti-sense oligonucleotides?

A
  • Antisense oligonucleotides

- Short modified nucleic acid complementary to target

47
Q

How do Anti-sense oligonucleotides work?

A
  1. Modification prevents degradation allow entry to cell
  2. Binds to target
  3. Block translation
  4. Can also alter splicing
  5. Relatively cheap to make
48
Q

What is in vivo therapy knockdown?

A
  • Useful for diseases caused by gain of function
  • Currently no successful therapies
  • Number in late stages of clinical trials
  • Ones closest to use oligonucleotides
  • RG6042 Huntington’s disease phase III trial
  • Mutation specific
49
Q

What is exon skipping?

A
  1. During pre-RNA processing
  2. Oligonucleotides cause exon to be skipped
  3. Can be used to skip disease causing exon
  4. To put RNA back in reading-frame
  5. Useful in limited circumstances
    6.Exons skipped mustn’t be vital
    Generally only large proteins

Year 1 POM (39 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions